Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.99USD
18 May 2018
Change (% chg)

$0.03 (+3.18%)
Prev Close
$0.96
Open
$0.97
Day's High
$1.00
Day's Low
$0.96
Volume
68,525
Avg. Vol
234,117
52-wk High
$6.77
52-wk Low
$0.79

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $50.18
Shares Outstanding(Mil.): 28.67
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -2.04 -- --
ROI: -97.45 1.57 14.38
ROE: -127.17 2.43 16.07

BRIEF-Genocea Biosciences Files For Mixed Shelf Of Up To $200 Mln

* GENOCEA BIOSCIENCES INC - FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (https://bit.ly/2GBQyfr) Further company coverage:

May 21 2018

BRIEF-Genocea Reports Qtrly Loss Per Share $0.21

* GENOCEA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

May 10 2018

BRIEF-Genocea Biosciences Enters Into Term Loan Facility Of $14 Million With Hercules

* GENOCEA BIOSCIENCES INC - ON APRIL 24, CO ENTERED INTO TERM LOAN FACILITY OF $14 MILLION WITH HERCULES

Apr 30 2018

BRIEF-Genocea Files IND For Neoantigen Cancer Vaccine Candidate Gen-009

* GENOCEA - FILES IND FOR NEOANTIGEN CANCER VACCINE CANDIDATE GEN-009, PLANS TO INITIATE PHASE 1/2A CLINICAL PROGRAM LATER THIS YEAR

Apr 30 2018

BRIEF-Genocea Biosciences Says Jonathan Poole Delivered Resignation As CFO

* GENOCEA BIOSCIENCES - ‍ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018​

Mar 09 2018

BRIEF-Genocea Qtrly Loss Per Share $0.37

* GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 15 2018

BRIEF-Genocea Biosciences Entered Into Agreement With Oncovir For Manufacture & Supply Of Hiltonol

* GENOCEA BIOSCIENCES SAYS ‍ON JAN 26, CO ENTERED INTO AGREEMENT WITH ONCOVIR FOR MANUFACTURE & SUPPLY OF HILTONOL(REG) (POLY-ICLC)​ - SEC FILING Source text: (http://bit.ly/2npDhjw) Further company coverage:

Jan 31 2018

BRIEF-Bvf Partners Reports A 8.9 Pct Passive Stake In Genocea Biosciences As Of Jan 17

* BVF PARTNERS L.P. REPORTS A 8.9 PERCENT PASSIVE STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text for Eikon: (http://bit.ly/2BDcCno) Further company coverage:

Jan 29 2018

BRIEF-New Enterprise Associates 16 Reports A 39.7 Pct Stake In Genocea Biosciences As Of Jan 17

* NEW ENTERPRISE ASSOCIATES 16, L.P. REPORTS A 39.7 PERCENT STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text: (http://bit.ly/2Gm4D1B) Further company coverage:

Jan 26 2018

BRIEF-Genocea Biosciences, Inc. Announces Pricing Of $55 Mln Concurrent Public Offerings

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PRICING OF $55 MILLION CONCURRENT PUBLIC OFFERINGS

Jan 17 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.16 -0.52
Pfizer Inc. (PFE.N) $35.97 +0.25
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Sanofi SA (SASY.PA) €66.23 -0.14
AstraZeneca plc (AZN.L) 5,454.00 0.00
GlaxoSmithKline plc (GSK.L) 1,507.60 -1.60
Vical Incorporated (VICL.OQ) $1.79 +0.07

Earnings vs. Estimates